Related references
Note: Only part of the references are listed.Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
Maria Gaibar et al.
JOURNAL OF ONCOLOGY (2020)
The force of HER2-A druggable target in NSCLC?
M. Jebbink et al.
CANCER TREATMENT REVIEWS (2020)
pH-Responsive Polymer Nanoparticles for Drug Delivery
Nayeleh Deirram et al.
MACROMOLECULAR RAPID COMMUNICATIONS (2019)
Dual Delivery of HNF4α and Cisplatin by Mesoporous Silica Nanoparticles Inhibits Cancer Pluripotency and Tumorigenicity in Hepatoma-Derived CD133-Expressing Stem Cells
Ping-Hsing Tsai et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters
Marta Smolinska et al.
DISEASE MARKERS (2019)
Polymers with controlled assembly and rigidity made with click-functional peptide bundles
Dongdong Wu et al.
NATURE (2019)
Synergistic Chemotherapy and Photodynamic Therapy of Endophthalmitis Mediated by Zeolitic Imidazolate Framework-Based Drug Delivery Systems
Hao Chen et al.
SMALL (2019)
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
Ana Godoy-Ortiz et al.
FRONTIERS IN ONCOLOGY (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
Dnyaneshwar Kalyane et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2019)
Combinational Effects of Active Targeting, Shape, and Enhanced Permeability and Retention for Cancer Theranostic Nanocarriers
Armin Tahmasbi Rad et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights
Maria Vallet-Regi et al.
MOLECULES (2018)
Recent progress in dendrimer-based nanomedicine development
Yejin Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2018)
Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors
Hyesun Hyun et al.
BIOMATERIALS (2018)
Cooperativity Principles in Self-Assembled Nanomedicine
Yang Li et al.
CHEMICAL REVIEWS (2018)
Dendrimer-based nanocarriers: a versatile platform for drug delivery
Hao-Jui Hsu et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2017)
High drug-loading nanomedicines: progress, current status, and prospects
Shihong Shen et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Light-switchable systems for remotely controlled drug delivery
Gayong Shim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy
Yang Li et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Cancer Cell Membrane-Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy
Ze Chen et al.
ACS NANO (2016)
The Penetrated Delivery of Drug and Energy to Tumors by Lipo-Graphene Nanosponges for Photolytic Therapy
Yu-Lin Su et al.
ACS NANO (2016)
Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells
Hai Wang et al.
BIOMATERIALS (2016)
Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging
Jonas G. Croissant et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Polysaccharide-based Noncovalent Assembly for Targeted Delivery of Taxol
Yang Yang et al.
SCIENTIFIC REPORTS (2016)
Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain
Hao Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility
Derrick Tarn et al.
ACCOUNTS OF CHEMICAL RESEARCH (2013)
Nanoparticles for Combination Drug Therapy
Liang Ma et al.
ACS NANO (2013)
Near-Infrared Light-Mediated Nanoplatforms for Cancer Thermo-Chemotherapy and Optical Imaging
Zhenjiang Zhang et al.
ADVANCED MATERIALS (2013)
Ultrasonic enhancement of drug penetration in solid tumors
Chun-Yen Lai et al.
FRONTIERS IN ONCOLOGY (2013)
Enhanced Tumor Treatment Using Biofunctional Indocyanine Green-Containing Nanostructure by Intratumoral or Intravenous Injection
Xiaohui Zheng et al.
MOLECULAR PHARMACEUTICS (2012)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging
Patricia Horcajada et al.
NATURE MATERIALS (2010)
Strategies in the design of nanoparticles for therapeutic applications
Robby A. Petros et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab
Alessandra Magnifico et al.
CLINICAL CANCER RESEARCH (2009)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Drug penetration in solid tumours
Andrew I. Minchinton et al.
NATURE REVIEWS CANCER (2006)
Exploiting the enhanced permeability and retention effect for tumor targeting
Arun K. Iyer et al.
DRUG DISCOVERY TODAY (2006)
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines
A Choudhury et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Degradation kinetics of indocyanine green in aqueous solution
V Saxena et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
